ALS-specific peptide composition
US7439324B2 · kind B2 · utility
16Cited by
1References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 3, 2006 |
| Grant date | Oct 21, 2008 |
| Priority date | — |
| Expiry date | Jun 24, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2828
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.